logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Idenix Pharmaceuticals, Inc.


USPTO Granted Patents = 100



Forward Citations = 3,393

Loading Chart...
Loading Chart...

71 inventors (with patents filed for the assignee):

goldMedal Jean-Pierre Sommadossi (30 out of 74 patents)

silverMedal Gilles J Gosselin (29 out of 51 patents)

bronzeMedal Cyril B Dousson (23 out of 26 patents)

4.  Dominique Surleraux (23 out of 23 patents)

5.  Francois-Rene Alexandre (22 out of 22 patents)

6.  David Dukhan (22 out of 25 patents)

7.  Christophe Parsy (21 out of 22 patents)

8.  Adel M Moussa (19 out of 61 patents)

9.  Benjamin Alexander Mayes (16 out of 17 patents)

10.  Claire Pierra (14 out of 14 patents)

11.  Alistair James Stewart (12 out of 13 patents)

12.  Paulo LaColla (12 out of 12 patents)

13.  Jean-Laurent Paparin (10 out of 14 patents)

14.  Richard Storer (10 out of 18 patents)

15.  Martin L Bryant (9 out of 27 patents)


Core Competencies:
Antiviral Compounds
Nucleoside Analogues
Phosphodiamide Prodrugs
Hepatitis C Treatment
Cyclic Phosphate Compounds
Serine Protease Inhibitors
Nucleotide Treatments
Flavivirus Inhibitors
Cancer Therapeutics
D-amino Acid Compounds
Purine Nucleotide Compounds
Phosphoramidate Compounds

100 patents:

1. 11123355 - Antiviral benzyl-amine phosphodiamide compounds (2021-09-21),
2. 11040975 - Carbocyclic nucleoside reverse transcriptase inhibitors (2021-06-22),
3. 10899788 - Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases (2021-01-26),
4. 10766917 - Nucleotides for the treatment of cancer (2020-09-08),
5. 10758557 - Methods and compositions for treating hepatitis C virus (2020-09-01),
6. 10745428 - Antiviral phosphodiamide prodrugs of tenofovir (2020-08-18),
7. 10736908 - Antiviral aryl-amide phosphodiamide compounds (2020-08-11),
8. 10723754 - 2',4′-bridged nucleosides for HCV infection (2020-07-28),
9. 10717758 - D-amino acid compounds for liver disease (2020-07-21),
10. 10683321 - 4'-or nucleosides for the treatment of HCV (2020-06-16),
11. 10525072 - 2'-branched nucleosides and flaviviridae mutation (2020-01-07),
12. 10519159 - Antiviral aliphatic ester prodrugs of tenofovir (2019-12-31),
13. 10513534 - 2'-chloro nucleoside analogs for HCV infection (2019-12-24),
14. 10449208 - Antiviral prodrugs of tenofovir (2019-10-22),
15. 10363265 - Methods and compositions for treating hepatitis C virus (2019-07-30),
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel antiviral drugs. With a deep understanding of viral diseases and expertise in medicinal chemistry, Idenix aims to provide innovative treatments to patients worldwide. Their research and development efforts are primarily directed towards hepatitis C virus (HCV) and other antiviral therapies. For more information about Idenix Pharmaceuticals, please visit their official website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

...
100 Patents

#27 in Cambridge, MA

#204 in Massachusetts

#3,652 in US

#7,559 in the World

...
Cambridge, MA, United States of America

Idenix Pharmaceuticals, Inc.

Forward Citations = 3,393

71 inventors:

goldMedal Jean-Pierre Sommadossi (30 out of 74 patents)

silverMedal Gilles J Gosselin (29 out of 51 patents)

bronzeMedal Cyril B Dousson (23 out of 26 patents)

4.  Dominique Surleraux (23 out of 23 patents)

5.  Francois-Rene Alexandre (22 out of 22 patents)

Please report any incorrect information to support@idiyas.com
Loading…